Sab Biotherapeutics Inc. Class WSABSWPreferred / convertible
13F holders, Q1 2025 (March 31)7holders −2
0new positions
2sold out
$0.03avg. 13F price*
At the end of Q1 2025, 7 institutions reported holding Sab Biotherapeutics Inc. Class W (SABSW) in their 13F filings, down 2 from Q4 2024. 0 opened new positions and 2 sold out. The largest holders were LMR Partners LLP ($19K), Morgan Stanley ($4K) and Yakira Capital Management, Inc. ($2K).
- Company
- Sab Biotherapeutics Inc. Class W
- CUSIP
- 78397T111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $126 |
All 13F filers, Q4 2024 → Q1 2025: 9,999 shares bought and 27,113 shares sold, net −17,114 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| LMR Partners LLP | — | No change | 539,588 | $19K |
| Morgan Stanley | — | No change | 146,439 | $4K |
| Yakira Capital Management, Inc. | — | Reduce -15.6% | 78,733 | $2K |
| HB Wealth Management, LLC | — | Add +20.0% | 60,000 | $2K |
| Walleye Trading LLC | — | Reduce -17.8% | 31,863 | $828 |
| Wolverine Asset Management LLC | — | Reduce -46.6% | 4,620 | $161 |
| NewEdge Advisors, LLC | — | No change | 1,072 | $28 |
"% of holder's portfolio" is SABSW's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. Class W the manager owns.